Black checkmark with a sparkle and a curved line underneath on a white background.
Company

NANOVIRICIDES, INC.

Ticker
NNVC
Sector
Industry
Report date
November 16, 2026
Valye AI Score

100

Very high visibility
Recent developments
Recent developments summary

Recent news coverage highlights NanoViricides among top biotech gainers and notes analyst recommendations, reflecting ongoing market interest and visibility.

Recent developments:
  • NanoViricides was featured among top biotech gainers in May 2026, indicating positive market activity and investor interest [N1].
  • The company was noted among top gainers in an after-hours rally in January 2026, reflecting trading momentum [N2].
  • Analyst EF Hutton reiterated a buy recommendation for NanoViricides in April 2023, signaling continued analyst support [N5].
  • NanoViricides has been mentioned in articles discussing small-cap biotech investment opportunities and nanotech stocks with potential, highlighting market recognition [N3][N4].
Overview

NanoViricides, Inc. is a clinical-stage biopharmaceutical company focused on developing antiviral drug candidates using nanotechnology. The company is headquartered in Shelton, Connecticut, and trades on the NYSE American exchange. Its business model involves conducting preclinical and clinical trials to develop therapies targeting viral infections. The company’s operations are subject to extensive regulatory oversight and clinical development risks. Financial disclosures indicate ongoing net losses and liquidity near parity with current liabilities as of the latest quarter ending September 30, 2026.

Executive summary

Financial figures (if any) are summarized from the latest available SEC filings and are provided for informational purposes only — not financial advice. NanoViricides, Inc. is a clinical-stage biopharmaceutical company developing nanotechnology-based antiviral therapies. As of September 30, 2026, the company reported cash and equivalents of approximately $2.58 million, current assets of $2.98 million, current liabilities of $3.15 million, a current ratio of 0.95, and a net loss of $5.74 million for the quarter. The company faces typical clinical trial risks including regulatory delays, patient enrollment challenges, and trial execution uncertainties. Recent news highlights NanoViricides among top biotech gainers and notes analyst recommendations, indicating market attention.

Scenarios for NNVC

Bull case model:

The company’s nanotechnology platform offers a novel approach to antiviral therapy, which could address unmet medical needs if clinical trials demonstrate safety and efficacy. Positive clinical milestones and regulatory progress could enhance the company’s value proposition. Market interest and analyst recommendations noted in recent news suggest recognition of the company’s potential in the biotech sector.

Bear case model:

Clinical development risks are significant, including potential delays, failures in clinical trials, regulatory hurdles, and challenges in patient enrollment and retention. The company’s financial position shows net losses and liquidity slightly below current liabilities, which may constrain operations without additional financing. Failure to achieve regulatory approval or commercialize products would materially impact the company’s prospects.

Moat:

NanoViricides’ moat is based on its proprietary nanotechnology platform for antiviral drug development, which aims to create targeted therapies potentially distinct from traditional antiviral approaches. The company’s clinical-stage pipeline and intellectual property related to nanoviricide technology contribute to its competitive positioning. However, as a clinical-stage company without approved products, its moat is contingent on successful clinical development and regulatory approval.

Risks overview
Risks summary
The most significant risks relate to clinical trial execution and regulatory approval uncertainties, combined with financial constraints that may impact the company’s ability to sustain operations and advance its drug candidates.
Risks details:

• Clinical Trial Risks: Clinical trials are expensive, time-consuming, and subject to regulatory scrutiny. Delays, redesigns, patient recruitment challenges, adverse safety findings, or lack of efficacy could delay or prevent product approval.
• Regulatory Approval Uncertainty: Regulatory authorities have discretion in approval decisions. The company’s drug candidates may not receive approval or may be approved with limited indications or labeling.
• Financial and Liquidity Risks: The company reported a net loss of $5.74 million for the quarter ended September 30, 2026, with current liabilities exceeding current assets slightly, indicating liquidity constraints that may require additional capital.
• Market and Competitive Risks: The biotech sector is competitive with alternative therapies and clinical trials underway by other companies. Market acceptance depends on successful clinical outcomes and regulatory approvals.

FINAL FORECAST FOR NNVC

Final take one line
NanoViricides, Inc. is a clinical-stage biotech company with a nanotechnology antiviral platform, facing typical clinical development and financial risks, with strong visibility from SEC filings and market coverage.
Final take 12 to 24 month view

Business trends: Continued clinical development of nanotechnology-based antiviral drug candidates with ongoing regulatory interactions and market interest.
Execution milestones: Progress in clinical trials, regulatory submissions, and potential achievement of key clinical endpoints.
Key risks: Clinical trial delays or failures, regulatory approval uncertainties, patient enrollment challenges, and financial liquidity constraints.

Valye AI Visibility Research Score

Very high visibility

Visibility score reflects the breadth and consistency of available disclosure across SEC filings, recent public reporting, and baseline business context (research-only; not investment advice).

100
LLM visibility overview
LLM Visibility known facts
  • NanoViricides, Inc. is a clinical-stage biopharmaceutical company focused on developing antiviral therapies using nanotechnology-based drug candidates.
  • The company is incorporated in Delaware and headquartered in Shelton, Connecticut, USA.
  • As of September 30, 2026, NanoViricides had cash and cash equivalents of approximately $2.58 million and current assets of about $2.98 million, with current liabilities of approximately $3.15 million, resulting in a current ratio of 0.95 and a cash ratio of 0.82, indicating near parity between current assets and liabilities.
  • For the quarter ended September 30, 2026, the company reported a net loss of approximately $5.74 million and basic and diluted earnings per share of -$0.23.
  • The company has approximately 25.5 million shares of common stock issued and outstanding as of September 28, 2026.
  • NanoViricides is engaged in clinical trials for its drug candidates, which are subject to extensive regulatory requirements and risks including delays, patient enrollment challenges, and potential safety or efficacy issues.
  • The company disclosed detailed risk factors related to clinical trial design, regulatory approval processes, patient recruitment and retention, and potential delays or failures in clinical development.
  • NanoViricides has issued shares for consulting and director services during the quarter ended September 30, 2026, recorded as expenses based on fair value at issuance.
  • The company has ongoing regulatory interactions including IND applications and clinical trial protocols subject to FDA and other regulatory authority review.
  • Recent news coverage highlights NanoViricides among top biotech gainers and notes analyst recommendations, reflecting market interest and visibility.
  • The company’s common stock is traded on the NYSE American exchange.
  • The company’s filings confirm it is not a shell company and is a smaller reporting company, not an accelerated filer.
  • The company’s forward-looking statements are subject to risks and uncertainties as disclosed in SEC filings.
  • The company’s business model centers on nanotechnology antiviral drug development with clinical trials underway or planned.
Sources
Sources - Context summary

Generated 2026-11-16

Sources - Earning calls
Sources - Other context
Sources - SEC Filings
  • S1 | 2026-09-28 | 10-K
  • S2 | 2026-11-16 | 10-Q
Sources - News headlines
  • N1 | 2026-05-28 | www.nasdaq.com | Top Biotech Gainers: QTTB Has A Good Hair Day, GH Wins ACS Recommendation, Ebola Lifts SNGX, NNVX | https://www.nasdaq.com/articles/top-biotech-gainers-qttb-has-good-hair-day-gh-wins-acs-recommendation-ebola-lifts-sngx
  • N2 | 2026-01-12 | www.nasdaq.com | After-Hours Rally: Zentalis, LifeMD, And NanoViricides Among Top Gainers | https://www.nasdaq.com/articles/after-hours-rally-zentalis-lifemd-and-nanoviricides-among-top-gainers
  • N3 | 2025-12-12 | www.nasdaq.com | 2 Small-Cap Biotechs That Could Reward Patient Investors | https://www.nasdaq.com/articles/2-small-cap-biotechs-could-reward-patient-investors
  • N4 | 2024-05-02 | www.nasdaq.com | 3 Nanotech Stocks With the Potential to Make You an Overnight Millionaire | https://www.nasdaq.com/articles/3-nanotech-stocks-with-the-potential-to-make-you-an-overnight-millionaire
  • N5 | 2023-04-19 | www.nasdaq.com | EF Hutton Reiterates NanoViricides (NNVC) Buy Recommendation | https://www.nasdaq.com/articles/ef-hutton-reiterates-nanoviricides-nnvc-buy-recommendation
  • N6 | 2022-08-17 | www.nasdaq.com | Pre-market Movers: HIL, BBBY, JCSE, SAVA, MX… | https://www.nasdaq.com/articles/pre-market-movers:-hil-bbby-jcse-sava-mx...
  • N7 | 2022-05-26 | www.nasdaq.com | Pre-market Movers: NTNX, WKME, SNOW, ISPC, NNVC… | https://www.nasdaq.com/articles/pre-market-movers:-ntnx-wkme-snow-ispc-nnvc...
  • N8 | 2022-01-18 | www.nasdaq.com | NanoViricides Inc. Shares Approach 52-Week Low - Market Mover | https://www.nasdaq.com/articles/nanoviricides-inc.-shares-approach-52-week-low-market-mover
Important legal disclaimer

This material is for informational purposes only and does not constitute investment, financial, legal or tax advice, or an offer or solicitation to buy or sell any security. The Valye AI Score is a model-based estimate derived from public information and is subject to change without notice. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information herein. Past performance is not indicative of future results. Investors should conduct their own research and consult a qualified financial adviser before making any investment decisions.

Blue logo with a stylized checkmark and star above the blue text 'VALYE' on a black background.

Generated by Valye SEC Pipeline Engine